Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial

201986 citationsJournal Articlebronze Open Access

Authors

Good health and well-being

Published in: The Lancet Oncology

Volume 20, Issue 6, pp. 862-876

Field-Weighted Citation Impact: 12.23